An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 in Combination With Oral BIBW 2992 in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit.

Trial Profile

An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 in Combination With Oral BIBW 2992 in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2015

At a glance

  • Drugs Afatinib (Primary) ; Volasertib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 14 Nov 2012 Planned End Date changed from 1 Oct 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov record.
    • 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 25 Jul 2012 Planned end date changed from 1 Jul 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top